Novel Pharmacological Treatments for the Prevention of Cardiovascular Events

Which agents to use and which patients benefit from the newer interventions?

Live Webinar was held on

24th November 2022

Organised and Endorsed by


Supported by an unrestricted educational grant from



This webinar focuses on the use of novel pharmacological treatment strategies aimed at improving cardiovascular outcomes in medium to high-risk patients. The focus will be on newer lipid lowering agents and novel antidiabetic drugs as well as on gaining insight into newer markers of cardiovascular risk, such as high Lp(a). DOACs and antiplatelet agents will be also discussed in the context of cardiovascular events prevention. The aim of the programme is to increase awareness as to the new advances in lipid lowering treatment and identify those patient subgroups who should benefit the most from these new therapies. The programme will be practical, clinically driven, informative and interactive and of interest to a range of healthcare professionals.


> To gain insight into newly emerging agents for the management of dyslipidaemia.

> To understand the role of Lpa in risk stratification.

> To discuss the use and indications of novel anti-diabetic agents for the prevention of cardiovascular events in patients with or without diabetes and CKD patients.


This educational programme is aimed at cardiologists, general medicine physicians, kidney specialists, lipid specialists, diabetologists, GPs, trainees in Cardiology, General Medicine and Nephrology, as well as nurses and other healthcare professionals with an interest in cardiovascular disease prevention.


Prof. Juan Carlos Kaski
Programme Director

Professor of Cardiovascular Science (Emeritus), St George’s, University of London, UK & Hon. Consultant Cardiologist, Cardiology Clinical Academic Group, St. George’s University Hospitals NHS Trust.

Prof. Kausik Ray
Co-Chair, Speaker & Panel Discussant 

Professor of Public Heath, Department of Public Health and Primary Care, Imperial College London & Honorary Consultant Cardiologist, Imperial College NHS Trust

Prof. Heinz Drexel
Co-Chair, Speaker & Panel Discussant

Head of the Department of Internal Medicine & Intensive Care, County Hospital Bregenz, Austria, CEO and Scientific Programme Director, VIVIT Institute, Feldkirch, Austria, Dean of the Medical and Scientific Faculty at Private University of the Principality of Liechtenstein

Prof. Ramzi Ajjan
Speaker & Panel Discussant

Professor of Metabolic Medicine & Consultant in Diabetes and Endocrinology, University of Leeds and Leeds Teaching Hospitals NHS Trust

Prof. Debasish Banerjee
Speaker & Panel Discussant

Consultant Nephrologist, Care Group Lead, Clinical Sub dean, St George’s University Hospital NHS Foundation Trust & Reader, St George’s, University of London, UK




Opening words and Introductions

Prof Juan Carlos Kaski

Practical strategies and new targets for the management of dyslipidaemia.
The role of PCSK-9 inhibitors. Should Lp (a) be a target? Why?

Prof Heinz Drexel

New advances in management of hypercholesterolaemia: new agents – Which patients benefit?
Icosapent ethyl, bempedoic acid, evinacumab, inclisiran.

Prof Kausik Ray

>> BREAK <<

Cardio renal therapies that improve cardiovascular outcomes

Prof Debasish Banerjee

Prevention of cardiovascular events in patients with diabetes –
SGLT2 inhibitors and GLPR1 agonists. How should diabetologists and cardiologists interact?

Prof Ramzi Ajjan

MDT-Presentation of 2 clinical cases to discuss:
Reducing “residual” cardiovascular risk – Lower is better – Side effects – The ESC guidelines for management of hyperlipidaemia. Newer strategies to improve outcomes in patients with diabetes.

All Faculty

Final Q&A session with live audience

All Faculty

Closing remarks and take away message. End of meeting

Prof Juan Carlos Kaski



This educational programme has been devised exclusively and independently by its scientific committee and is organised in collaboration with St George’s, University of London (SGUL) and endorsed by the International Society of Cardiovascular Pharmacotherapy (ISCP).




The programme is also supported by Novartis UK who has provided an unrestricted educational grant to partially cover organisational costs and has had no input into the agenda or content of this educational activity.



Save your spot right now


Missed to attend Live? Watch it On-Demand!

Technical Partner


Not recently active